We may have often heard the elders in our family boast about the properties of Neem and its use in treating many physical ailments and diseases. But what about the infamous coronavirus? Does our trusty old Neem tree have any chances of protecting against it? A recent study has suggested that this may be actually possible!

According to a new study led by scientists at the University of Colorado Anschutz Medical Campus and the Indian Institute of Science Education and Research Kolkata, extract from the bark of the Neem tree may help treat and reduce the spread of coronavirus.

The study was published in the journal, ‘Virology’.

The study reported showed that components of Neem bark may target a wide range of viral proteins, suggesting its potential as an antiviral agent against emerging variants of coronaviruses (including SARS-CoV-2).

The Neem tree, indigenous to India, has been used for thousands of years for its anti-parasitic, anti-bacterial and antiviral properties. The bark extract has helped treat malaria, stomach and intestinal ulcers, skin diseases and many other diseases.

“The goal of this research is to develop a Neem-based medication that can reduce the risk of serious illness when someone is infected with coronaviruses,” said study co-author Maria Nagel, MD, research professor in the department of neurology and ophthalmology at the University Of Colorado School Of Medicine on the CU Anschutz Medical Campus.

“We hope that scientists won’t have to continuously develop new therapies every time a new SARS-CoV-2 variant emerges,” she said. “Just like how we take penicillin for strep throat, we envision taking the Neem-based drug for COVID, allowing us to resume our normal lives without fear of hospitalization and death.”

The scientists investigated the impact of the bark extract against coronaviruses in their laboratories. In India, researchers tested it in animal models and showed that it had antiviral properties against coronavirus. Using computer modeling, the researchers predicted that Neem bark extract will bind to the SARS-CoV-2 spike protein at various locations, preventing virus entry to host cells.

At CU Anschutz, Nagel’s lab tested the Neem bark extract in SARS-CoV-2 human lung cells. It proved as effective as a preventive drug for infection and also decreased virus replication and spread after infection.

“The next step in our research is to identify the specific components in Neem bark extract that are antiviral. Because these components bind to various regions of SARS-CoV-2, we believe that it will be effective on emerging variants with spike mutations,” said Nagel. “We will then determine the formulation of dosage for an antiviral drug to treat coronavirus infections.”

The scientists said this research could guide new antiviral therapeutic efforts to combat the ongoing pandemic while holding out the promise for treating new coronavirus strains.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor